OncoDxRx Honing Unique Transformative Technologies for Personalized Diagnostic Capability

Los Angeles, California — The startup company OncoDxRx is developing novel diagnostic and therapeutic technologies to provide increased customization and effectiveness for the unmet cancer care. The company has completed the validation of a novel technology dubbed “PGA” (Patient-derived Gene expression-informed Anti-cancer drug efficacy) with the goal of establishing personalized and precision medicine for the 70-80% cancer population who currently not qualified for targeted therapy or immunotherapy. For now, only 20-30% patients are eligible for precision medicine after biomarker testing.

“Patient needs and turnaround time are particularly important factors for a future diagnostic and therapeutic capability,” the company said.

“The industry has worked a lot on next-generation sequencing and precision medicine, but little by little, it has gotten sidetracked,” the company added. “Is there a way to rebuild our focus? Can a cheaper, faster and automated PCR-based system take on this task?”

OncoDxRx emphasized that it has no intention of pursuing expensive, complex and sophisticated systems, but is interested in “easy, rapid deployable platforms,” where infrastructure and training already in place in most laboratories.

There will be some “coherence” with the company’s other one-of-its-kind pipelines, such as the multi-cancer early detection (MCED), minimal residual disease (MRD) assays and the DNA repair activity test which are in different development phases.

OncoDxRx’s goal is to move quickly and complete three PGA validation first (PGA lung, PGA pancreatic and PGA breast), and seeking for investors/partners and licensing/buyout opportunity in parallel, the company noted.

OncoDxRx said the company wants to get out of the habit of asking industry what capabilities can be developed, and industry asking what capabilities the community is actually looking for. “This vicious cycle can go on for a long time,” the company noted.